Sporadic Reappearance of Minute Amounts of Hepatitis C Virus RNA After Successful Therapy Stimulates Cellular Immune Responses

Immunology Section, NIDDK, National Institutes of Health, DHHS, Bethesda, Maryland 20892-1800, USA.
Gastroenterology (Impact Factor: 16.72). 10/2010; 140(2):676-685.e1. DOI: 10.1053/j.gastro.2010.10.048
Source: PubMed


Several studies have reported hepatitis C virus (HCV) RNA sequences in the circulation after treatment-induced or spontaneous recovery. We investigated whether the HCV RNA represents persistence of HCV infection or reinfection.
We studied 117 patients who recovered from HCV infection (98 following therapy and 19 spontaneously). A reverse-transcription polymerase chain reaction assay was used to detect the 5'-untranslated region of HCV. T-cell responses were studied by enzyme-linked immunospot for interferon-γ.
Plasma samples from 15% of treatment-recovered patients and no spontaneously recovered patient tested positive for HCV RNA. Lymphocytes from 3 patients who responded to therapy and 1 who recovered spontaneously tested positive. The frequency of HCV RNA detection in plasma correlated inversely with the time after the end of treatment. Post-treatment HCV 5'-untranslated region sequences matched pretreatment sequences in 85% of cases. T-cell responses were significantly greater at time points with detectable trace amounts of HCV RNA than at time points without detectable HCV RNA (P = .035) and were primarily against nonstructural HCV antigens. The immune hierarchy was preserved over 5 years in patients whose post-treatment HCV RNA sequences matched pretreatment sequences, indicating HCV RNA persistence. An altered immune hierarchy with dominant immune responses, shifting from nonstructural to structural antigens, was observed in a single patient whose post-treatment HCV genotype differed from that of the pretreatment genotype, indicating HCV reinfection.
Trace amounts of HCV RNA of pretreatment sequence persisted and reappeared sporadically in the circulation within 8 years after recovery from hepatitis C but not thereafter, indicating that patients are cured of HCV infection. Reappearance of HCV RNA induced HCV-specific T-cell responses.

Download full-text


Available from: Sukanya Raghuraman, Oct 06, 2014
  • Source
    • "These findings also support the observations of Zerbini et al. [10] who reported that HBV-specific immune responses are not altered in OBI and that lasting memory T-cell responses present in anti-HBc positive individuals with OBI could be important for maintaining viremia under control. Moreover, as it has been demonstrated recently in HCV infection [31], Th1 responses may be sustained by circulating activated T-cells in subjects with OBI and transient or persistent low HBV viremia. Both CD4 + and CD8 + antigen-specific T cells were identified in our OBI and spontaneous resolver groups; hence, the mechanism that contributed to maintain low viral replication included acquired CD4 + and CD8 + T cell responses, although CD4 + responses seemed stronger. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Occult HBV infection (OBI) is defined by the presence of HBV DNA in the liver and/or serum and negative HBsAg testing. Since the implementation of highly sensitive HBV DNA screening, OBI is also detected in healthy blood donors. The aims of this study were to investigate HBV-specific immune responses and genetic variability in donors with OBI, established by HBV DNA in serum. HBV-specific T-cell responses to HBV antigens were tested in 34 OBI donors by IFN-γ ELISpot, cytometric bead array, and intracellular cytokine staining. As comparison populations, 36 inactive HBV carriers, 22 donors with spontaneously resolved HBV infection, 24 vaccinated donors, and 25 seronegative donors were also included. Surface, pre-S, and pre-c/core genes from 44 genotype D isolates (24 OBI and 20 HBsAg-positive) were sequenced. The immune response of OBI donors to the 3 HBV antigens was 29-41%, similar to the response in subjects with resolved HBV infection and higher than that in HBsAg-positive subjects. On sequence analysis, OBI donors presented a higher HBsAg mutation rate than HBsAg-positive subjects. Mutations were clustered in the major hydrophilic region of HBsAg, and no stop codons or relevant mutations that could affect antigen formation or detection were observed. Our results suggest that immune response can suppress viral replication to low levels and HBsAg expression to undetectable levels in OBI blood donors. Relevant mutations were not found in the genomic HBsAg coding region. Hence, the fact that HBsAg was not detected in OBI is likely due to low HBsAg production, rather than to a failure of laboratory reagents.
    Journal of Hepatology 12/2011; 56(4):765-74. DOI:10.1016/j.jhep.2011.11.011 · 11.34 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Following infection with the hepatitis C virus (HCV), in most cases immunity fails to eradicate the virus, resulting in slowly progressing immunopathology in the HCV-infected liver. We are the first to examine intrahepatic T cells and CD4(+) CD25(+) FoxP3(+) regulatory T cells (Treg) in patients chronically infected with HCV (chronic HCV patients) during and after antiviral therapy by collecting multiple aspiration biopsy samples from the liver at different time points. We found that intrahepatic Treg frequencies were increased upon alpha interferon and ribavirin administration in about 50% of chronic HCV patients, suggesting stronger regulation of intrahepatic immunity by Treg during antiviral therapy. After cessation of antiviral therapy, the frequency of intrahepatic Treg remained above baseline in the large majority of livers of individuals who successfully cleared the virus. The phenotype of those Treg that were retained in the liver months after therapy-induced clearance of HCV RNA indicated a reduced contribution of effector memory cells. Our findings, gathered by multiple samplings of the liver, indicate that successful antiviral therapy of chronic HCV patients does not lead to normalization of the local immune response to a resting state comparable to that for healthy livers. The continuous presence of high numbers of Treg, with a phenotype reflecting a relatively weak suppressive activity, suggests ongoing residual regulation of immunopathology. These findings provide important insight into the dynamics of the immune response to HCV, as well as the effect of therapy on intrahepatic immunity.
    Journal of Virology 03/2011; 85(11):5323-30. DOI:10.1128/JVI.02551-10 · 4.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Polymerase chain reaction (PCR) assays are the standard for detecting hepatitis C virus viremia. The transcription-mediated amplification (TMA)-based assay is more sensitive. We retrospectively reviewed the charts of patients with a post-end of treatment (EOT) PCR-/TMA+ result to assess the clinical significance of a positive TMA result after a PCR negative EOT response or sustained viral response (SVR). Patients were divided into Group 1: PCR-/TMA+ after EOT response but during 24 week follow-up (n = 4); and Group 2: PCR-/TMA+ after SVR (n = 11). All Group 1 patients achieved SVR. No Group 2 patients became PCR positive or had a rise in ALT. The TMA subsequently became negative in 6/7 patients with follow-up evaluation. A discordant positive TMA post-EOT response or SVR did not seem to be clinically significant. This finding supports the possibility that patients with SVR have an acquired immune surveillance that prevents low-level viremia from progressing to clinical relapse.
    Digestive Diseases and Sciences 07/2011; 57(1):239-42. DOI:10.1007/s10620-011-1820-x · 2.61 Impact Factor
Show more